View Filing Data

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Aug. 07, 2017
Document Entity Information [Abstract]
Entity Registrant Name	BioScrip, Inc.
Entity Central Index Key	0001014739
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		127,475,226

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 40,533	$ 9,569
Restricted cash	5,055	0
Receivables, less allowance for doubtful accounts of $45,651 and $44,730 as of June 30, 2017 and December 31, 2016, respectively	103,089	111,811
Inventory	28,822	36,165
Prepaid expenses and other current assets	12,998	18,507
Total current assets	190,497	176,052
Property and equipment, net	30,063	32,535
Goodwill	365,947	365,947
Intangible assets, net	24,672	31,043
Other non-current assets	2,204	2,163
Total assets	613,383	607,740
Current liabilities
Current portion of long-term debt	1,731	18,521
Accounts payable	46,381	59,134
Amounts due to plan sponsors	4,825	3,799
Accrued interest	6,736	6,705
Accrued expenses and other current liabilities	43,209	42,191
Total current liabilities	102,882	130,350
Long-term debt, net of current portion	475,674	433,413
Deferred taxes	3,504	2,281
Other non-current liabilities	17,942	1,257
Total liabilities	600,002	567,301
Stockholders’ deficit
Preferred stock, $.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively	0	0
Common stock, $.0001 par value; 250,000,000 shares authorized; 127,441,893 and 117,682,543 shares issued and outstanding as of June 30, 2017 and December 31, 2016, respectively	13	12
Additional paid-in capital	628,545	611,844
Accumulated deficit	(692,045)	(643,419)
Total stockholders’ deficit	(63,487)	(31,563)
Total liabilities and stockholders’ deficit	613,383	607,740
Series A convertible preferred stock, $.0001 par value; 825,000 shares authorized; 21,645 shares issued and outstanding as of June 30, 2017 and December 31, 2016; and $2,754 and $2,603 liquidation preference as of June 30, 2017 and December 31, 2016, respectively
Current liabilities
Convertible preferred stock	2,639	2,462
Series C convertible preferred stock, $.0001 par value; 625,000 shares authorized; 614,177 shares issued and outstanding as of June 30, 2017 and December 31, 2016; and $79,858 and $75,491 liquidation preference as of June 30, 2017 and December 31, 2016, respectively
Current liabilities
Convertible preferred stock	$ 74,229	$ 69,540

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Allowance for doubtful accounts	$ 45,651	$ 44,730
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares, issued (in shares)	127,441,893	117,682,543
Common stock, shares, outstanding (in shares)	127,441,893	117,682,543
Series A Preferred Stock
Convertible preferred stock series, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock series, shares authorized (in shares)	825,000	825,000
Convertible preferred stock series, shares issued (in shares)	21,645	21,645
Convertible preferred stock series, shares outstanding (in shares)	21,645	21,645
Convertible preferred stock series, liquidation preference	$ 2,754	$ 2,603
Series C Preferred Stock
Convertible preferred stock series, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock series, shares authorized (in shares)	625,000	625,000
Convertible preferred stock series, shares issued (in shares)	614,177	614,177
Convertible preferred stock series, shares outstanding (in shares)	614,177	614,177
Convertible preferred stock series, liquidation preference	$ 79,858	$ 75,491

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Net revenue	$ 218,106	$ 232,462	$ 435,916	$ 470,924
Cost of revenue (excluding depreciation expense)	149,796	168,298	302,022	342,528
Gross profit	68,310	64,164	133,894	128,396
Other operating expenses	42,486	40,619	86,844	80,277
Bad debt expense	6,223	4,279	13,387	11,871
General and administrative expenses	10,025	9,414	19,504	20,465
Restructuring, acquisition, integration, and other expenses, net	3,911	4,291	7,134	6,958
Depreciation and amortization expense	6,789	4,252	13,777	8,790
Interest expense	12,715	9,469	25,459	18,881
Loss on extinguishment of debt	13,453	0	13,453	0
Loss (gain) on dispositions	685	0	685	(939)
Loss from continuing operations, before income taxes	(27,977)	(8,160)	(46,349)	(17,907)
Income tax expense	718	149	1,337	172
Loss from continuing operations, net of income taxes	(28,695)	(8,309)	(47,686)	(18,079)
(Loss) income from discontinued operations, net of income taxes	(503)	75	(940)	308
Net loss	(29,198)	(8,234)	(48,626)	(17,771)
Accrued dividends on preferred stock	(2,303)	(2,056)	(4,517)	(4,054)
Deemed dividends on preferred stock	(175)	(173)	(349)	(345)
Loss attributable to common stockholders	$ (31,676)	$ (10,463)	$ (53,492)	$ (22,170)
Loss per common share:
Loss from continuing operations, basic and diluted (in dollars per share)	$ (0.26)	$ (0.14)	$ (0.44)	$ (0.32)
Loss from discontinued operations, basic and diluted (in dollars per share)	0.00	0.00	(0.01)	0.00
Loss per common share, basic and diluted (in dollars per share)	$ (0.26)	$ (0.14)	$ (0.45)	$ (0.32)
Weighted average common shares outstanding, basic and diluted (in shares)	121,189	73,186	119,993	70,978

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net loss	$ (48,626)	$ (17,771)
Less: (Loss) income from discontinued operations, net of income taxes	(940)	308
Loss from continuing operations, net of income taxes	(47,686)	(18,079)
Adjustments to reconcile net loss from continuing operations, net of income taxes to net cash used in operating activities:
Depreciation and amortization	13,777	8,790
Amortization of deferred financing costs and debt discount	2,875	1,987
Change in fair value of contingent consideration	0	102
Change in deferred income tax	1,223	352
Compensation under stock-based compensation plans	1,027	1,993
Loss (gain) on dispositions	685	(939)
Loss on extinguishment of debt	13,453	0
Changes in assets and liabilities:
Receivables, net of bad debt expense	8,721	(1,281)
Inventory	7,343	10,537
Prepaid expenses and other assets	5,469	322
Accounts payable	(12,753)	(16,190)
Amounts due to plan sponsors	1,027	62
Accrued interest	31	(192)
Accrued expenses and other liabilities	714	(3,140)
Net cash used in operating activities from continuing operations	(4,094)	(15,676)
Net cash used in operating activities from discontinued operations	(940)	(5,913)
Net cash used in operating activities	(5,034)	(21,589)
Cash flows from investing activities:
Purchases of property and equipment	(4,292)	(5,466)
Proceeds from dispositions	0	1,132
Investment in restricted cash	(5,055)	0
Net cash used in investing activities	(9,347)	(4,334)
Cash flows from financing activities:
Proceeds from priming credit agreement, net of expenses	23,060	0
Fees attributable to extinguishment of debt	(311)	0
Net proceeds from issuance of equity, net of issuance costs	20,776	83,267
Borrowings on long-term debt, net of expenses	294,446	0
Borrowings on revolving credit facility	563	45,000
Repayments on revolving credit facility	(55,863)	(60,000)
Principal payments of long-term debt	(236,770)	(6,274)
Repayments of capital leases	(401)	(129)
Other	(155)	(93)
Net cash provided by financing activities	45,345	61,771
Net change in cash and cash equivalents	30,964	35,848
Cash and cash equivalents - beginning of period	9,569	15,577
Cash and cash equivalents - end of period	40,533	51,425
DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for interest	22,613	17,325
Cash paid during the period for income taxes	249	229
DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Entry into capital lease	$ 1,327	$ 0

BASIS OF PRESENTATION

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

BASIS OF PRESENTATION

These Unaudited Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements, including the notes thereto, and other information included in the Annual Report on Form 10-K of BioScrip, Inc. and its wholly-owned subsidiaries (the “Company”) for the year ended December 31, 2016 (the “Annual Report”) filed with the U.S. Securities and Exchange Commission (“SEC”). These Unaudited Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, and the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.

The information furnished in these Unaudited Consolidated Financial Statements reflects all adjustments, including normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. Operating results for the three months and six months ended June 30, 2017 require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes and are not necessarily indicative of the results that may be expected for the full year ending December 31, 2017.

The Unaudited Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Business Combinations

Business combinations are accounted for using the acquisition method as of the acquisition date, the date on which control is transferred to the Company. Goodwill is measured at the acquisition date as the fair value of the consideration transferred, plus the fair value of the identifiable assets acquired and liabilities assumed. Transaction costs are expensed as incurred. Contingent consideration payable is measured at fair value at the acquisition date. Contingent consideration classified as equity is not re-measured and settlement is accounted for within equity.

Reclassifications

Prior period financial statement amounts have been reclassified to conform to current period presentation.

Cash and Cash Equivalents and Restricted Cash

Highly liquid investments with a maturity of three months or less when purchased are classified as cash equivalents. Restricted cash consists of cash balances held by financial institutions as collateral for letters of credit. These balances are reclassified to cash and cash equivalents when the underlying obligation is satisfied, or in accordance with the governing agreement. Restricted cash balances expected to become unrestricted during the next twelve months are recorded as current assets. As of June 30, 2017, the Company had a restricted cash balance, in a money market account, of $5.1 million to cash collateralize outstanding letters of credit.

Collectability of Accounts Receivable

The following table sets forth the aging of our net accounts receivable (net of allowance for contractual adjustments, and prior to allowance for doubtful accounts), aged based on date of service and categorized based on the three primary overall types of accounts receivable characteristics (in thousands):



	June 30, 2017							December 31, 2016
	0 - 180 days		Over 180 days		Total			0 - 180 days		Over 180 days		Total
Government	$	18,714	$	7,512	$	26,226		$	19,891	$	8,278	$	28,169
Commercial	84,190		23,589		107,779			97,744		19,848		117,592
Patient	5,195		9,540		14,735			3,955		6,825		10,780
Gross accounts receivable	$	108,099	$	40,641	148,740			$	121,590	$	34,951	156,541
Allowance for doubtful accounts					(45,651		)					(44,730		)
Net accounts receivable					$	103,089						$	111,811

Recent Accounting Pronouncements

In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-11—Earnings Per Share (Topic 260), Distinguishing Liabilities From Equity (Topic 480), and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 eliminates the requirement that a down round feature precludes equity classification when assessing whether an instrument is indexed to an entity’s own stock. A freestanding equity-linked financial instrument no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. The effective date for ASU 2017-11 is for annual or any interim periods beginning after December 15, 2018. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.

In May 2017, the FASB issued ASU 2017-09—Compensation–Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-09 modifies when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the same immediately before and after a change to the terms and conditions of the award. The effective date for ASU 2017-09 is for annual or any interim periods beginning after December 15, 2017. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.

In January 2017, the FASB issued ASU 2017-04—Intangibles–Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. ASU 2017-04 modifies the accounting for goodwill impairment. The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The effective date for ASU 2017-04 is for annual or any interim periods beginning after December 15, 2019. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.

In November 2016, the FASB issued ASU 2016-18—Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The effective date for ASU 2016-18 is for annual or any interim periods beginning after December 15, 2017. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15—Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 provides guidance for eight specific cash flow issues with respect to how cash receipts and cash payments are classified in the statements of cash flows, with the objective of reducing diversity in practice. The effective date for ASU 2016-15 is for annual periods beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02—Leases (Topic 842), requiring lessees to recognize a right-of-use asset and a lease liability on the balance sheet for all leases with the exception of short-term leases. For lessees, leases will continue to be classified as either operating or finance leases in the income statement. The effective date of the new standard for public companies is for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition and requires application of the new guidance at the beginning of the earliest comparative period presented. The Company is evaluating the effect that the updated standard will have on its consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09—Revenue from Contracts with Customers (Topic 606). The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The FASB delayed the effective date to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. In addition, in March and April 2016, the FASB issued new guidance intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. Both amendments permit the use of either a retrospective or cumulative effect transition method and are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early application permitted. The Company has not elected early adoption and will apply the modified retrospective approach upon adoption. The Company continues to evaluate the impact of the adoption of the new revenue standard on its consolidated financial statements.

LOSS PER SHARE

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Loss Per Share

LOSS PER SHARE

The Company presents basic and diluted loss per share for its common stock, par value $0.0001 per share (“Common Stock”). Basic loss per share is calculated by dividing the net loss attributable to common stockholders of the Company by the weighted average number of shares of Common Stock outstanding during the period. Diluted loss per share is determined by adjusting the profit or loss attributable to stockholders and the weighted average number of shares of Common Stock outstanding adjusted for the effects of all dilutive potential common shares comprised of options granted, unvested restricted stocks, stock appreciation rights, warrants and Series A and Series C Preferred Stock (as defined below). Potential Common Stock equivalents that have been issued by the Company related to outstanding stock options, unvested restricted stock and warrants are determined using the treasury stock method, while potential common shares related to Series A and Series C Preferred Stock are determined using the “if converted” method.

The Company's Series A Convertible Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”), and Series C Convertible Preferred Stock, par value $0.0001 per share (the “Series C Preferred Stock” and, together with the Series A Preferred Stock, the “Preferred Stock”), is considered a participating security, which means the security may participate in undistributed earnings with Common Stock. The holders of the Preferred Stock would be entitled to share in dividends, on an as-converted basis, if the holders of Common Stock were to receive dividends. The Company is required to use the two-class method when computing loss per share when it has a security that qualifies as a participating security. The two-class method is an earnings allocation formula that determines loss per share for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. In determining the amount of net earnings to allocate to common stockholders, earnings are allocated to both common and participating securities based on their respective weighted-average shares outstanding during the period. Diluted loss per share for the Company’s Common Stock is computed using the more dilutive of the two-class method or the if-converted method.

The following table sets forth the computation of basic and diluted loss per common share (in thousands, except for per share amounts):



	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Numerator:
Loss from continuing operations, net of income taxes	$	(28,695	)	$	(8,309	)	$	(47,686	)	$	(18,079	)
Income (loss) from discontinued operations, net of income taxes	(503		)	75			(940		)	308
Net loss	$	(29,198	)	$	(8,234	)	$	(48,626	)	$	(17,771	)
Accrued dividends on preferred stock	(2,303		)	(2,056		)	(4,517		)	(4,054		)
Deemed dividend on preferred stock	(175		)	(173		)	(349		)	(345		)
Loss attributable to common stockholders	$	(31,676	)	$	(10,463	)	$	(53,492	)	$	(22,170	)

Denominator - Basic and Diluted:
Weighted average common shares outstanding	121,189			73,186			119,993			70,978

Loss per Common Share:
Loss from continuing operations, basic and diluted	$	(0.26	)	$	(0.14	)	$	(0.44	)	$	(0.32	)
Loss from discontinued operations, basic and diluted	—			—			(0.01		)	—
Loss per common share, basic and diluted	$	(0.26	)	$	(0.14	)	$	(0.45	)	$	(0.32	)

The loss attributable to common stockholders is used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. Accordingly, the computation of diluted shares for the three months ended June 30, 2017 and 2016 excludes the effect of 18.3 million and 14.0 million shares, respectively, and the computation of the diluted shares for the six months ended June 30, 2017 and 2016 excludes the effect of 18.4 million and 15.5 million shares, respectively, issued in connection with the PIPE Transaction and the Rights Offering, as well as the 2017 Warrants (see Note 3 - Stockholders’ Deficit), stock options and restricted stock awards, as their inclusion would be anti-dilutive to loss attributable to common stockholders.

STOCKHOLDERS' DEFICIT

6 Months Ended

Jun. 30, 2017

Equity [Abstract]

Stockholders' Deficit

STOCKHOLDERS’ DEFICIT

Securities Purchase Agreement

On March 9, 2015, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with Coliseum Capital Partners L.P., a Delaware limited partnership, Coliseum Capital Partners II, L.P., a Delaware limited partnership, and Blackwell Partners, LLC, Series A, a Georgia limited liability company (collectively, the “PIPE Investors”). Pursuant to the terms of the Purchase Agreement, the Company issued and sold to the PIPE Investors in a private placement (the “PIPE Transaction”) an aggregate of (a) 625,000 shares of Series A Preferred Stock at a purchase price per share of $100.00, (b) 1,800,000 Class A warrants (the “Class A Warrants”), and (c) 1,800,000 Class B warrants (the “Class B Warrants” and, together with Class A Warrants, the “PIPE Warrants”), for gross proceeds of $62.5 million. The initial conversion price for the Series A Preferred Stock is $5.17. The PIPE Warrants may be exercised to acquire shares of Common Stock. Pursuant to an addendum (the “Warrant Addendum”), dated as of March 23, 2015, to the Warrant Agreement, dated as of March 9, 2015, with the PIPE Investors, the PIPE Investors paid the Company $0.5 million in the aggregate, and the per share exercise price of the Class A Warrants and Class B Warrants was set at $5.17 and $6.45, respectively, reduced from $5.295 to $5.17 and from $6.595 to $6.45, respectively.

Series A, Series B, and Series C Convertible Preferred Stock

In connection with the PIPE Transaction, the Company authorized 825,000 shares and issued 625,000 shares of Series A Preferred Stock at $100.00 per share. In connection with the Rights Offering (as defined below), the Company issued an additional 10,822 shares of Series A Preferred Stock at $100.00 per share. The Series A Preferred Stock may, at the option of the holder, be converted into Common Stock and receive a Liquidation Preference upon voluntary or involuntary liquidation, dissolution, or winding up of the Company as described in the Annual Report. The Company may pay a noncumulative cash dividend on each share of the Series A Preferred Stock as previously disclosed in the Annual Report. In the event the Company does not declare and pay a cash dividend, the Liquidation Preference of the Series A Preferred Stock will be increased to an amount equal to the Liquidation Preference in effect at the start of the applicable quarterly dividend period, plus an amount equal to such then applicable Liquidation Preference multiplied by 11.5% per annum.

On June 10, 2016, in order to allow the shares of Common Stock reserved for issuance for the conversion of the Series A Preferred Stock and exercise of the PIPE Warrants to be released from reservation and sold pursuant to the 2016 Equity Offering (see below), we entered into an Exchange Agreement with the PIPE Investors (the “Series B Exchange Agreement”) pursuant to which the PIPE Investors agreed:

to exchange 614,177 shares of the existing Series A Preferred Stock for an identical number of shares of Series B Convertible Preferred Stock (the “Series B Preferred Stock”), which have the same terms as the Series A Preferred Stock previously described in the Company’s prior public filings, except that the terms of the Series B Preferred Stock include the authority of the holders of the Series B Preferred Stock to waive the requirement that the Company reserve a sufficient number of shares of Common Stock reserved at all times to allow for the conversion of the Series B Preferred Stock; and


ii)	to waive the requirement under the Warrant Agreement governing the PIPE Warrants to reserve 3,600,000 shares of our Common Stock for the exercise of the PIPE Warrants.

On June 14, 2016, the Company entered into another Exchange Agreement (the “Series C Exchange Agreement”) with the PIPE Investors, pursuant to which the PIPE Investors agreed to exchange their shares of Series B Preferred Stock issued pursuant to the Series B Exchange Agreement on a one for one basis for shares of Series C Preferred Stock.

Under the terms of the Series C Exchange Agreement, the PIPE Investors agreed to exchange 614,177 shares of the Series B Preferred Stock for an identical number of shares of Series C Preferred Stock, which have the same terms as the Series B Preferred Stock, except that the terms of the Series C Preferred Stock provide that the 11.5% per annum rate of non-cash dividends payable on the shares of the Series C Preferred Stock will be reduced based on the achievement by the Company of specified “Consolidated EBITDA” as defined in the Senior Credit Facilities. In addition, pursuant to the Series C Exchange Agreement, the PIPE Investors agreed to waive the requirement under the Warrant Agreement governing the PIPE Warrants held by the PIPE Investors to reserve 3,600,000 shares of Common Stock for the exercise of the PIPE Warrants.

As a result of the exchanges discussed above, there are, as of June 30, 2017, (a) 21,645 shares of Series A Preferred Stock outstanding, of which 10,823 shares are owned by the PIPE Investors, (b) no shares of Series B Preferred Stock outstanding, and (c) 614,177 shares of Series C Preferred Stock outstanding, all of which are owned by the PIPE Investors.

As of June 30, 2017, the Liquidation Preference of the Series A Preferred Stock and Series C Preferred Stock was $2.8 million and $79.9 million, respectively.

PIPE Warrants

In connection with the PIPE Transaction, the Company issued 1,800,000 Class A Warrants and 1,800,000 Class B Warrants which may be exercised to acquire shares of Common Stock. The rights and terms of the Class A Warrants and the Class B Warrants are identical except for the exercise price. Pursuant to the Warrant Addendum with the PIPE Investors, the PIPE Investors paid the Company $0.5 million in the aggregate, and the per share exercise price of the Class A Warrants and Class B Warrants was set at $5.17 and $6.45, respectively, reduced from $5.295 to $5.17 and from $6.595 to $6.45, respectively.

The Company entered into a registration rights agreement, as amended (the “Registration Rights Agreement”), with the PIPE Investors that, among other things and subject to certain exceptions, requires the Company, upon the request of the PIPE Investors, to register the Common Stock of the Company issuable upon conversion of the PIPE Investors’ Series A Preferred Shares, the Series C Preferred Shares, or exercise of the PIPE Warrants. Pursuant to the terms of the Registration Rights Agreement, the costs incurred in connection with such registrations will be borne by the Company. As provided under the Registration Rights Agreement, the Company on April 1, 2016 filed a shelf registration statement on Form S-3 under the Securities Act of 1933, as amended (the “Securities Act”), to register, among other things, the Common Stock of the Company issuable upon conversion of the PIPE Investors’ Series A and Series C Preferred Shares.

Rights Offering

On June 30, 2015, the Company commenced a rights offering (the “Rights Offering”) pursuant to which the Company distributed subscription rights to purchase units consisting of (1) Series A Preferred Stock, each share convertible into shares of Common Stock at a conversion price of $5.17 per share, (2) Class A warrants to purchase one share of Common Stock at a price of $5.17 per share (the “Public Class A Warrants”), and (3) Class B warrants to purchase one share of Common Stock at a price of $6.45 per share (the “Public Class B Warrants” and, together with the Public Class A Warrants, the “Public Warrants”). The Rights Offering expired on July 27, 2015 and was completed on July 31, 2015. Stockholders of the Company exercised subscription rights to purchase 10,822 units, consisting of an aggregate of 10,822 shares of the Series A Preferred Stock, 31,025 Public Class A Warrants, and 31,025 Public Class B Warrants, at a subscription price of $100.00 per unit. Pursuant to the Rights Offering, the Company raised gross proceeds of approximately $1.1 million.

With the exception of the expiration date, the Class A Warrants issued pursuant to the PIPE Transaction, as amended by the Warrant Addendum, have the same terms as the Public Class A Warrants issued pursuant to the Rights Offering. Similarly, with the exception of the expiration date, the Class B Warrants issued pursuant to the PIPE Transaction, as amended by the Warrant Addendum, have the same terms as the Public Class B Warrants issued pursuant to the Rights Offering.

Carrying Value of Series A Preferred Stock

As of June 30, 2017, the following values were accreted pursuant to the terms of the Exchange Agreement, dated as of June 10, 2016, among the Company and the signatories thereto and recorded as a reduction of additional paid in capital in Stockholders’ Deficit and a deemed dividend on the Unaudited Consolidated Statements of Operations. In addition, dividends were accrued at 11.5% from the date of issuance to June 30, 2017. The following table sets forth the activity recorded during the six months ended June 30, 2017 related to the Series A Preferred Stock (in thousands):



Series A Preferred Stock carrying value at December 31, 2016	$	2,462
Accretion of discount related to issuance costs	26
Dividends recorded through June 30, 2017¹	151
Series A Preferred Stock carrying value June 30, 2017	$	2,639

¹Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.

Carrying Value of Series C Preferred Stock

As of June 30, 2017, the following values were accreted pursuant to the terms of the Exchange Agreement, dated as of June 16, 2016, among the Company and the signatories thereto and recorded as a reduction of additional paid in capital in Stockholders’ Deficit and a deemed dividend on the Unaudited Consolidated Statements of Operations. In addition, dividends were accrued at 11.5% from the date of issuance to June 30, 2017. The following table sets forth the activity recorded during the six months ended June 30, 2017 related to the Series C Preferred Stock (in thousands):



Series C Preferred Stock carrying value at December 31, 2016	$	69,540
Accretion of discount related to issuance costs	323
Dividends recorded through June 30, 2017¹	4,366
Series C Preferred Stock carrying value June 30, 2017	$	74,229

¹Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.

Shelf Registration Statement

The Company filed a shelf registration statement on Form S-3 under the Securities Act on April 1, 2016, which was declared effective May 2, 2016 (the “2016 Shelf”). Under the 2016 Shelf at the time of effectiveness, the Company had the ability to raise up to $200.0 million, in one or more transactions, by selling Common Stock, preferred stock, debt securities, warrants, units and rights.

2016 Equity Offering

On June 22, 2016 the Company completed an underwritten public offering of 45,200,000 shares of Common Stock, including 5,200,000 shares of Common Stock issued upon the underwriters’ full exercise of the over-allotment option, at a public offering price of $2.00 per share, less underwriting discounts and commissions and offering expenses payable by us (the “2016 Equity Offering”). The Company received net proceeds of approximately $83.3 million from the 2016 Equity Offering, after deducting underwriting discounts and commissions and offering costs.

A portion of the net proceeds from the 2016 Equity Offering was used to fund the Cash Consideration (as defined below) and pay fees and expenses in connection with the closing of the Home Solutions Transaction (see below).

Home Solutions Transaction

On September 9, 2016, the Company acquired substantially all of the assets and assumed certain liabilities of HS Infusion Holdings, Inc. (“Home Solutions”) and its subsidiaries (the “Home Solutions Transaction”) pursuant to an Asset Purchase Agreement dated June 11, 2016 (as amended, the “Home Solutions Agreement”), by and among Home Solutions, a Delaware corporation, certain subsidiaries of Home Solutions, the Company and HomeChoice Partners, Inc., a Delaware corporation. Home Solutions, a privately held company, provides home infusion and home nursing products and services to patients suffering from chronic and acute medical conditions. On June 16, 2016, the Company, HomeChoice Partners, Inc. and Home Solutions entered into an amendment to the Home Solutions Agreement (the “First Amendment”), which modified the terms of the consideration payable by the Company to Home Solutions thereunder. On September 2, 2016, the same parties entered into a second amendment to the Home Solutions Agreement (the “Second Amendment”), which amended the Home Solutions Agreement to eliminate the condition to closing that the Company receive stockholder approval to increase its authorized share capital (the “Charter Amendment”) and facilitated the timely consummation of the Home Solutions Transaction. The Second Amendment instead provided that the Company will hold a stockholder meeting after the closing of the Home Solutions Transaction to seek stockholder approval of the Charter Amendment, and if the approval is not obtained at the first special meeting, the Company will submit the proposal on a twice per year basis beginning in 2017, at either the annual meeting or a special meeting of stockholders. The Charter Amendment was approved at a special meeting of stockholders held on November 30, 2016.

The aggregate consideration paid by the Company in the Home Solutions Transaction was equal to (i) $67.5 million in cash (the “Cash Consideration”); plus (ii) (a) 3,750,000 shares of Company common stock (the “Transaction Closing Equity Consideration”) and (b) the right to receive contingent equity securities of the Company, in the form of restricted shares of Company common stock (the “RSUs”), issuable in two tranches, Tranche A and Tranche B, with different vesting conditions (collectively, the “Contingent Shares”). The number of shares of Company common stock in Tranche A is 3.1 million and the number of shares of Company common stock in Tranche B is 4.0 million, each subject to certain vesting conditions. Upon close of the Home Solutions Transaction the RSUs had no intrinsic value, but are reported in our consolidated financial statements at their estimated fair value at the date of issuance. The Home Solutions Agreement provides Home Solutions with certain customary registration rights that required us, within 30 days following the closing of the Home Solutions Transaction, to file a registration statement for the selling stockholder’s resale of the Transaction Closing Equity Consideration and the Contingent Shares pursuant to the Securities Act. The Company filed the registration statement on October 7, 2016 and it was declared effective on October 27, 2016.

The Company will issue the shares of our Common Stock issuable to Home Solutions pursuant to the RSUs in Tranche A promptly, and in any event within five business days, following the earlier of (a) the closing price of our Common Stock, as reported by NASDAQ, averaging $4.00 per share or above over 20 consecutive trading days during the period beginning on September 9, 2016 and ending December 31, 2019, or (b) a change of control that occurs on or prior to December 31, 2017 or a change of control thereafter but on or prior to December 31, 2019, pursuant to which the consideration payable per share equals or exceeds $4.00 per share. The Company will issue the shares of our Common Stock issuable to Home Solutions pursuant to the RSUs in Tranche B promptly, and in any event within five business days, following the earlier of (a) the closing price of our Common Stock, as reported by NASDAQ, averaging $5.00 per share or above over 20 consecutive trading days during the period beginning on September 9, 2016 and ending December 31, 2019, or (b) a change of control that occurs on or prior to December 31, 2017, or a change of control thereafter but on or prior to December 31, 2019, pursuant to which the consideration payable per share equals or exceeds $5.00 per share. The Home Solutions Agreement provides for a cash settlement option related to the RSUs, effective June 15, 2021, if, and only if, authorized shares are unavailable when the vesting conditions of Tranche A and Tranche B are met. At the date of acquisition, the Company did not have sufficient authorized shares available to satisfy the issuance of Tranche A and Tranche B RSUs and, accordingly, recognized a liability for the fair value of the contingent consideration. As of November 30, 2016, upon approval of the Charter Amendment, the Company had sufficient authorized shares available should the vesting conditions be met and the RSUs become issuable. The liability was reclassified to equity and a gain on the change in the fair value of the RSUs was recognized as of November 30, 2016. On March 13, 2017, the Company filed with the SEC a Registration Statement on Form S-3 to register the Contingent Shares and it was declared effective on April 18, 2017.

The Cash Consideration and the Transaction Closing Equity Consideration were paid at closing and were funded by cash on-hand and borrowings from our Revolving Credit Facility.

First Quarter 2017 Private Placement

On March 1, 2017, the Company entered into a Stock Purchase Agreement (the “First Quarter Stock Purchase Agreement”) with Venor Capital Master Fund Ltd., Map 139 Segregated Portfolio of LMA SPC, Venor Special Situations Fund II LP and Trevithick LP (the “First Quarter Stockholders”). Pursuant to the First Quarter Stock Purchase Agreement, the Company sold an aggregate of 3.3 million shares of its common stock (the “First Quarter Shares”) for aggregate gross proceeds of approximately $5.1 million in a private placement transaction (the “First Quarter 2017 Private Placement”). The purchase price for each Share was $1.5366, which was negotiated between the Company and the First Quarter Stockholders based on the volume-weighted average price of the Company's common stock on the NASDAQ Global Market on March 1, 2017.

In connection with the First Quarter 2017 Private Placement, the Company entered into a Registration Rights Agreement (the “First Quarter 2017 Registration Rights Agreement”) with the First Quarter Stockholders. Pursuant to the First Quarter 2017 Registration Rights Agreement, the Company agreed to prepare and file a registration statement with the SEC within ten days of the date it files its annual report on Form 10-K for the fiscal year ended December 31, 2016, for purposes of registering the resale of the First Quarter Shares and any shares of common stock issued as a dividend or other distribution with respect to the First Quarter Shares.

As provided under the First Quarter 2017 Registration Rights Agreement, the Company, on March 13, 2017, filed a shelf registration statement on Form S-3 under the Securities Act to register the First Quarter Shares and it was declared effective April 18, 2017.

Proceeds from the First Quarter 2017 Private Placement were used for working capital and general corporate purposes.

2017 Warrants

In connection with the Second Lien Note Facility (as defined below), the Company also issued warrants (the “2017 Warrants”) to the purchasers of the Second Lien Notes (as defined below) pursuant to a Warrant Purchase Agreement dated as of June 29, 2017 (the “Warrant Purchase Agreement”). The 2017 Warrants entitle the purchasers of the Warrants to purchase shares of Common Stock, representing at the time of any exercise of the 2017 Warrants an equivalent number of shares equal to 4.99% of the Common Stock of the Company on a fully diluted basis, subject to the terms of the Warrant Agreement governing the Warrants, dated as of June 29, 2017 (the “Warrant Agreement”); provided, however, the Warrants may not be converted to the extent that, after giving effect to such conversion, the holders of the 2017 Warrants would beneficially own, in the aggregate, in excess of (i) 19.99% of the shares of Common Stock outstanding as of June 29, 2017 (the “Closing Date”) minus (ii) the shares of Common Stock that were sold pursuant to the Second Quarter 2017 Private Placement (as defined below) (the “Conversion Cap”). The Conversion Cap will not apply to the 2017 Warrants if the Company obtains the approval of its stockholders for the removal of the Conversion Cap, which the Company is required to take certain steps to attempt to obtain, subject to the terms of the Warrant Agreement.

The 2017 Warrants have a 10-year term and an initial exercise price of $2.00 per share, and may be exercised by payment of the exercise price in cash or surrender of shares of Common Stock into which the Warrants are being converted in an aggregate amount sufficient to pay the exercise price. The exercise price and the number of shares that may be acquired upon exercise of the 2017 Warrants is subject to adjustment in certain situations, including price based anti-dilution protection whereby, subject to certain exceptions, if the Company later issues Common Stock or certain Common Stock Equivalents (as defined in the Warrant Agreement) at a price less than either the then-current market price per share or exercise price of the 2017 Warrants, then the exercise price will be decreased and the percentage of shares of Common Stock issuable upon exercise of the Warrants will remain the same, giving effect to such issuance. Additionally, the 2017 Warrants have standard anti-dilution protections if the Company effects a stock split, subdivision, reclassification or combination of its Common Stock or fixes a record date for the making of a dividend or distribution to stockholders of cash or certain assets. Upon the occurrence of certain business combinations the 2017 Warrants will be converted into the right to acquire shares of stock or other securities or property (including cash) of the successor entity.

Second Quarter 2017 Private Placement

On June 29, 2017, the Company entered into a Stock Purchase Agreement (the “Second Quarter Stock Purchase Agreement”) with a fund managed by Ares Management L.P. (“Ares” or the “Second Quarter Stock Purchaser”). Pursuant to the terms of the Second Quarter Stock Purchase Agreement, the Company issued and sold to the Second Quarter Stock Purchaser in a private placement (the “Second Quarter 2017 Private Placement”) 6,359,350 shares of Common Stock (the “Second Quarter Shares”) at a price of $2.50 per share, for proceeds of approximately $15.9 million, net of $0.2 million in associated costs.

Second Quarter Registration Rights Agreement

In connection with the 2017 Warrants and the Second Quarter 2017 Private Placement, the Company entered into a Registration Rights Agreement (the “Second Quarter 2017 Registration Rights Agreement”) with the holders of the 2017 Warrants and the Second Quarter Stock Purchaser. Pursuant to the Second Quarter 2017 Registration Rights Agreement, subject to certain exceptions, the Company is required, upon the request of the Second Quarter Stock Purchaser and holders of the 2017 Warrants, to register the resale of the Second Quarter Shares and the shares of Common Stock issuable upon exercise of the 2017 Warrants. Pursuant to the terms of the Second Quarter 2017 Registration Rights Agreement, these registration rights will not become effective until twelve months after the Closing Date, and the costs incurred in connection with such registrations will be borne by the Company.

ACQUISITIONS

6 Months Ended

Jun. 30, 2017

Business Combinations [Abstract]

Acquisitions

ACQUISITIONS

On September 9, 2016, the Company completed the Home Solutions Transaction pursuant to the Home Solutions Agreement. The aggregate consideration paid by the Company in the Home Solutions Transaction was equal to (i) the Cash Consideration; plus (ii)(a) the Transaction Closing Equity Consideration and (b) the RSUs, issuable in two tranches, Tranche A and Tranche B, with different vesting conditions. The number of shares of Company common stock in Tranche A is 3.1 million and the number of shares of Company common stock in Tranche B is 4.0 million, each subject to vesting conditions (see Note 3 - Stockholders’ Deficit). Upon close of the Home Solutions Transaction the RSUs had no intrinsic value, but are reported in our consolidated financial statements at their estimated fair value at the date of issuance. Upon approval of the Charter Amendment on November 30, 2016, the date at which sufficient shares were available should the RSUs vest and become issuable, the liability was remeasured to its then-current fair value and reclassified to equity.

The following table sets forth the consideration transferred in connection with the acquisition of Home Solutions as of September 9, 2016 (in thousands):



Cash	$	67,516
Equity issued at closing	9,938
Capital lease obligation assumed	301
Fair value of contingent consideration	15,400
Total consideration	$	93,155

The following table sets forth the preliminary estimate of fair value of the assets acquired and liabilities assumed upon acquisition of Home Solutions (in thousands):



Accounts receivable	$	11,956
Inventories	3,199
Prepaids and other assets	852
Total current assets	$	16,007
Property and equipment	4,651
Goodwill	57,218
Managed care contracts	24,700
Licenses	5,400
Trade name	1,800
Non-compete agreements	200
Other non-current assets	891
Total assets	$	110,867
Accounts payable	14,576
Accrued liabilities	3,136
Current liabilities	$	17,712
Total fair value of cash and contingent consideration	$	93,155

The excess of the purchase price over the fair value of the tangible and identifiable intangible assets acquired and liabilities assumed in the acquisition was allocated to goodwill. The value of the goodwill represents the value the Company expects to be created by combining the operations of the companies, including the ability to cross-sell its services on a national basis with an expanded footprint in home infusion and the opportunity to focus on higher margin therapies.

In accordance with ASC Topic 805 Business Combinations (“ASC 805”), the allocation of the purchase price is subject to adjustment during the measurement period after the closing date (September 9, 2016) when additional information on assets and liability valuations becomes available. The Company has not finalized its valuation of certain assets and liabilities recorded pursuant to the acquisition including intangible assets and contingent consideration. Thus, the provisional measurements recorded are subject to change. Any changes will be recorded as adjustments to the fair value of the assets and liabilities with residual amounts allocated to goodwill.

Under the Home Solutions Agreement, the Company did not purchase, among other things, any accounts receivable associated with governmental payors. However, the Home Solutions Agreement stipulates that collections of government receivables, as of the first anniversary of the closing date, in an amount less than the amount estimated as government receivables in the Closing Certificate, must be paid to the seller. The Company continues to evaluate the collectability of the government receivables and will record a liability in the event collections fall short of the guarantee.

RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES, NET

6 Months Ended

Jun. 30, 2017

Restructuring and Related Activities [Abstract]

Restructuring, Acquisition, Integration, and Other Expenses, Net

RESTRUCTURING, ACQUISITION, INTEGRATION, AND OTHER EXPENSES, NET

Restructuring, acquisition, integration and other expenses include non-operating costs associated with restructuring, acquisition, and integration initiatives such as employee severance costs, certain legal and professional fees, training costs, redundant wage costs, impacts recorded from the change in contingent consideration obligations, and other costs related to contract terminations and closed branches/offices.

Restructuring, acquisition, integration, and other expenses, net in the Unaudited Consolidated Statements of Operations for the three months and six months ended June 30, 2017 and 2016 consisted of the following (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Restructuring expense	$	3,648	$	1,316	$	6,854	$	3,932
Acquisition and integration expense	263		2,924		280		2,924
Change in fair value of contingent consideration	—		51		—		102
Total restructuring, acquisition, integration, and other expense, net	$	3,911	$	4,291	$	7,134	$	6,958

DEBT

6 Months Ended

Jun. 30, 2017

Debt Disclosure [Abstract]

Debt

DEBT

As of June 30, 2017 and December 31, 2016, the Company’s debt consisted of the following (in thousands):



	June 30, 2017			December 31, 2016
Senior Credit Facilities	$	—		$	265,507
First Lien Note Facility, net of unamortized discount	198,000			—
Second Lien Note Facility, net of unamortized discount	82,931			—
2021 Notes, net of unamortized discount	197,008			196,670
Capital leases	3,134			2,209
Less: Deferred financing costs	(3,668		)	(12,452		)
Total Debt	477,405			451,934
Less: Current portion	(1,731		)	(18,521		)
Long-term debt, net of current portion	$	475,674		$	433,413

Debt Facilities

The Company was previously obligated under (i) a senior secured first-lien revolving credit facility in an aggregate principal amount of $75.0 million (the “Revolving Credit Facility”), (ii) a senior secured first-lien term loan B in an aggregate principal amount of $250.0 million (the “Term Loan B Facility”) and (iii) a senior secured first-lien delayed draw term loan B in an aggregate principal amount of $150.0 million (the “Delayed Draw Term Loan Facility” and, together with the Revolving Credit Facility and the Term Loan B Facility, the “Senior Credit Facilities”) with SunTrust Bank (“SunTrust”), Jefferies Finance LLC and Morgan Stanley Senior Funding, Inc., originally entered on July 31, 2013 and amended from time to time.

On January 6, 2017, the Company entered into a credit agreement (the “Priming Credit Agreement” and, together with the Senior Credit Facilities, the “Prior Credit Agreements”) with certain existing lenders under the Senior Credit Facilities and SunTrust, as administrative agent for itself and the lenders. The Priming Credit Agreement provided an aggregate borrowing commitment of $25.0 million, which was fully drawn at closing.

On June 29, 2017 (the “Closing Date”), the Company entered into (i) a first lien note purchase agreement (the “First Lien Note Facility”), among the Company, which is the issuer under the agreement, the financial institutions and note purchasers from time to time party to the agreement (the “First Lien Note Purchasers”), and Wells Fargo Bank, National Association, in its capacity as collateral agent for itself and the First Lien Note Purchasers (the “First Lien Collateral Agent”), pursuant to which the Company issued first lien senior secured notes in an aggregate principal amount of $200.0 million (the “First Lien Notes”); and (ii) a second lien note purchase agreement (the “Second Lien Note Facility” and, together with the First Lien Note Facility, the “Notes Facilities”) among the Company, which is the issuer under the agreement, the financial institutions and note purchasers from time to time party to the agreement (the “Second Lien Note Purchasers”), and Wells Fargo Bank, National Association, in its capacity as collateral agent for itself and the Second Lien Note Purchasers (the “Second Lien Collateral Agent” and, together with the First Lien Collateral Agent, the “Collateral Agent”), pursuant to which the Company (a) issued second lien senior secured notes in an aggregate initial principal amount of $100.0 million (the “Initial Second Lien Notes”) and (b) has the ability to draw upon the Second Lien Note Facility and issue second lien delayed draw senior secured notes in an aggregate initial principal amount of $10.0 million for a period of 18 months after the Closing Date, subject to certain terms and conditions (the “Second Lien Delayed Draw Notes” and, together with the Initial Second Lien Notes, the “Second Lien Notes”; the Second Lien Notes, together with the First Lien Notes, the “Notes”). Funds managed by Ares are acting as lead purchasers for the Notes Facilities.

The Company used the proceeds of the sale of the First Lien Notes and the Initial Second Lien Notes to repay in full all amounts outstanding under the Prior Credit Agreements and extinguished the liability. Each of the Prior Credit Agreements was terminated following such repayment. The Company used the remaining proceeds of $15.9 million, net of $0.2 million in issuance costs, from the Notes Facilities and the Second Quarter 2017 Private Placement for working capital and general corporate purposes.

The First Lien Notes accrue interest, payable monthly in arrears, at a floating rate or rates equal to, at the option of the Company, (i) the base rate (defined as the highest of the Federal Funds Rate plus 0.5% per annum, the Prime Rate as published by The Wall Street Journal and the one-month London Interbank Offered Rate (“LIBOR”) (subject to a 1.0% floor) plus 1.0%), or (ii) the one-month LIBOR rate (subject to a 1.0% floor), plus a margin of 6.0% if the base rate is selected or 7.0% if the LIBOR Option is selected. The First Lien Notes mature on August 15, 2020, provided that if the Company’s existing 8.875% Senior Notes due 2021 (the “2021 Notes”) are refinanced prior to August 15, 2020, then the scheduled maturity date of the First Lien Notes shall be June 30, 2022.

The First Lien Notes will amortize in equal quarterly installments equal to 0.625% of the aggregate principal amount of the First Lien Note Facility, commencing on September 30, 2019, and on the last day of each third month thereafter, with the balance payable at maturity. The First Lien Notes are pre-payable at the Company’s option at specified premiums to the principal amount that will decline over the term of the First Lien Note Facility. If the First Lien Notes are prepaid prior to the second anniversary of the Closing Date, the Company will be required to pay a make-whole premium based on the present value (using a discount rate based on the specified treasury rate plus 50 basis points) of all remaining interest payments on the First Lien Notes being prepaid prior to the second anniversary of the Closing Date, plus 4.0% of the principal amount of First Lien Notes being prepaid. On or after the second anniversary of the Closing Date, the prepayment premium is 4.0%, which declines to 2.0% on or after the third anniversary of the Closing Date, and declines to 0.0% on or after the fourth anniversary of the Closing Date. At any time, the Company may pre-pay up to $50.0 million in aggregate principal amount of the First Lien Notes from internally generated cash without incurring any make-whole or prepayment premium. The occurrence of certain events of default may increase the applicable rate of interest by 2.0% and could result in the acceleration of the Company’s obligations under the First Lien Note Facility prior to stated maturity and an obligation of the Company to pay the full amount of its obligations under the First Lien Note Facility.

The First Lien Note Facility contains customary events of default that include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material indebtedness and events constituting a change of control. In addition, the obligations under the First Lien Note Facility will be guaranteed by joint and several guarantees from the Company’s subsidiaries.

In connection with the First Lien Note Facility, the Company, its subsidiaries and the First Lien Collateral Agent entered into a First Lien Guaranty and Security Agreement, dated as of June 29, 2017 (the “First Lien Guaranty and Security Agreement”). Pursuant to the First Lien Guaranty and Security Agreement, the obligations under the First Lien Notes will be secured by first priority liens on, and security interests in, substantially all of the assets of the Company and its subsidiaries.

The Second Lien Notes accrue interest, payable monthly in arrears, at a floating rate or rates equal to, at the option of the Company, (i) one-month LIBOR (subject to a 1.25% floor) plus 9.25% per annum in cash, (ii) one-month LIBOR (subject to a 1.25% floor) plus 11.25% per annum, which amount will be capitalized on each interest payment date, or (iii) one-month LIBOR (subject to a 1.25% floor) plus 10.25% per annum, of which one-half LIBOR plus 4.625% per annum will be payable in cash and one-half LIBOR plus 5.625% per annum will be capitalized on each interest payment date, provided that, in each case, if any permitted refinancing indebtedness with which the 2021 Notes are refinanced requires or permits the payment of cash interest, all of the interest on the Second Lien Notes shall be paid in cash. The Second Lien Notes mature on August 15, 2020, provided that if the 2021 Notes are refinanced prior to August 15, 2020, then the scheduled maturity date of the Second Lien Notes shall be June 30, 2022.

In connection with the Second Lien Note Facility, the Company also issued warrants (the “2017 Warrants”) to the purchasers of the Second Lien Notes pursuant to a Warrant Purchase Agreement dated as of June 29, 2017 (the “Warrant Purchase Agreement”). The 2017 Warrants entitle the purchasers of the Warrants to purchase shares of Common Stock, representing at the time of any exercise of the 2017 Warrants an equivalent number of shares equal to 4.99% of the Common Stock of the Company on a fully diluted basis, subject to the terms of the Warrant Agreement governing the Warrants, dated as of June 29, 2017 (the “Warrant Agreement”). The 2017 Warrants, considered a derivative and subject to remeasurement at each reporting period, are reflected in other non-current liabilities at a fair value of $16.9 million.

The Second Lien Notes are not subject to scheduled amortization installments. The Second Lien Notes are pre-payable at the Company’s option at specified premiums to the principal amount that will decline over the term of the Second Lien Note Facility. If the Second Lien Notes are prepaid prior to the third anniversary of the Closing Date, the Company will need to pay a make-whole premium based on the present value (using a discount rate based on the specified treasury rate plus 50 basis points) of all remaining interest payments on the Second Lien Notes being prepaid prior to the third anniversary of the Closing Date, plus 4.0% of the principal amount of Second Lien Notes being prepaid. On or after the third anniversary of the Closing Date, the prepayment premium is 4.0%, which declines to 2.0% on or after the fourth anniversary of the Closing Date, and declines to 0.0% on or after the fifth anniversary of the Closing Date. The occurrence of certain events of default may increase the applicable rate of interest by 2.0% and could result in the acceleration of the Company’s obligations under the Second Lien Note Facility prior to stated maturity and an obligation of the Company to pay the full amount of its obligations under the Second Lien Note Facility.

The Second Lien Note Facility contains customary events of default that include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material indebtedness and events constituting a change of control. In addition, the obligations under the Second Lien Note Facility will be guaranteed by joint and several guarantees from the Company’s subsidiaries.

In connection with the Second Lien Note Facility, the Company, its subsidiaries and the Second Lien Collateral Agent entered into a Second Lien Guaranty and Security Agreement, dated as of June 29, 2017 (the “Second Lien Guaranty and Security Agreement”). Pursuant to the Second Lien Guaranty and Security Agreement, the obligations under the Second Lien Notes will be secured by second priority liens on, and security interests in, substantially all of the assets of the Company and its subsidies.

In connection with the First Lien Note Facility and the Second Lien Note Facility, the Company, the First Lien Collateral Agent and the Second Lien Collateral Agent, entered into an intercreditor agreement containing customary provisions to, among other things, subordinate the lien priority of the liens granted under the Second Lien Note Facility to the liens granted under the First Lien Note Facility.

2021 Notes

On February 11, 2014, the Company issued $200.0 million aggregate principal amount of the 2021 Notes. The 2021 Notes are senior unsecured obligations of the Company and are fully and unconditionally guaranteed by all existing and future subsidiaries of the Company.

Interest on the 2021 Notes accrues at a fixed rate of 8.875% per annum and is payable in cash semi-annually on February 15 and August 15 of each year. The debt discount of $5.0 million at issuance is being amortized as interest expense through maturity which will result in the accretion over time of the outstanding debt balance to the principal amount. The 2021 Notes are the Company’s senior unsecured obligations and rank equally in right of payment with all of its other existing and future senior unsecured indebtedness and senior in right of payment to all of its existing and future subordinated indebtedness.

The 2021 Notes are guaranteed on a full, joint and several basis by each of the Company’s existing and future domestic restricted subsidiaries that is a borrower under any of the Company’s credit facilities or that guarantees any of the Company’s debt or that of any of its restricted subsidiaries, in each case incurred under the Company’s credit facilities. As of June 30, 2017, the Company does not have any independent assets or operations, and as a result, its direct and indirect subsidiaries (other than minor subsidiaries), each being 100% owned by the Company, are fully and unconditionally, jointly and severally, providing guarantees on a senior unsecured basis to the 2021 Notes.

Fair Value of Financial Instruments

The following details our financial instruments where the carrying value and the fair value differ (in thousands):



Financial Instrument	Carrying Value as of June 30, 2017		Markets for Identical Item (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
First Lien Note Facility	$	198,000	$	—	$	198,000	$	—
Second Lien Note Facility	82,931		—		82,931		—
2017 Warrants	16,908		—		16,908		—
2021 Notes	197,008		—		178,109		—
Total	$	494,847	$	—	$	475,948	$	—

The fair value hierarchy for disclosure of fair value measurements is as follows:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Quoted prices, other than quoted prices included in Level 1, which are observable for the assets or liabilities, either directly or indirectly.

Level 3: Inputs that are unobservable for the assets or liabilities. Financial assets with carrying values approximating fair value include cash and cash equivalents and accounts receivable. Financial liabilities with carrying values approximating fair value include accounts payable and capital leases. The carrying value of these financial assets and liabilities approximates fair value due to their short maturities.

COMMITMENTS AND CONTINGENCIES	6 Months Ended
COMMITMENTS AND CONTINGENCIES	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES Legal Proceedings Breach of Contract Litigation in the Delaware Court of Chancery On November 3, 2015, Walgreen Co. and various affiliates (“Walgreens”) filed a lawsuit in the Delaware Court of Chancery against the Company and certain of its subsidiaries (collectively, the “Defendants”). The complaint alleges that the Company breached certain non-compete provisions contained in the Community Pharmacy and Mail Business Purchase Agreement dated as of February 1, 2012, by and among Walgreens and certain subsidiaries and the Company and certain subsidiaries. The complaint seeks both money damages and injunctive relief. On December 7, 2015, the Defendants filed a motion to dismiss the case. Walgreens filed an answering brief on January 11, 2016 and the Defendants filed a reply on January 25, 2016. On March 11, 2016, the Court held oral argument on the Company’s motion to dismiss and granted the motion, holding that Walgreens’ breach of contract claims for money damages must be resolved in accordance with the 2012 Purchase Agreement’s alternative dispute resolution procedure. On March 15, 2016, Walgreens informed the Court that it would not be pursuing any claims for injunctive relief in the Court at that time, but instead would engage in the required alternative dispute resolution procedure. Walgreens requested that the Court keep the case open pending the results of that process. On March 16, 2016, the Court stayed the lawsuit and removed the trial from its calendar, but did not grant Walgreens any other relief or enjoin the Company from taking any action. On December 8, 2016, the parties submitted the dispute to an arbitrator. On December 28, 2016, the arbitrator rendered its decision, finding that the Company had not violated the non-compete, except for certain limited sales of oral oncology, HIV and transplant pharmaceuticals, constituting approximately 3 percent of the total sales that Walgreens claimed were made in violation of the agreement. The arbitrator also concluded that Walgreens was not entitled to recover its lost profits or lost revenues as a result of any such sales. Despite that ruling, the arbitrator awarded Walgreens $5.8 million in damages, or approximately 20 percent of the total amount requested. Such amount is included as a component of Accrued expenses and other current liabilities within the Consolidated Balance Sheets as of June 30, 2017 (unaudited) and December 31, 2016. The Company believes that arbitrator’s damages award ignored applicable law, contradicted the arbitrator’s liability findings and exceeded the scope of the arbitrator’s authority in light of both parties’ arbitration submissions. Accordingly, on January 13, 2017, the Company filed a motion to vacate the arbitration award. On February 10, 2017, Walgreens opposed the Company’s motion and filed a motion to confirm the arbitration award and for other relief. On July 19, 2017, the Court confirmed the arbitration award and denied Walgreens’ request for injunctive relief. The Company intends to continue to vigorously defend itself, but the Company can provide no assurance that any continued challenge to the award will be successful. Derivative Lawsuit in the Delaware Court of Chancery On May 7, 2015, a derivative complaint was filed in the Delaware Court of Chancery (the “Derivative Complaint”) by the Park Employees’ & Retirement Board Employees’ Annuity & Benefit Fund of Chicago (the “Derivative Plaintiff”). The Derivative Complaint names as defendants certain current and former directors of the Company, consisting of Richard M. Smith, Myron Holubiak, Charlotte Collins, Samuel Frieder, David Hubers, Richard Robbins, Stuart Samuels and Gordon Woodward (collectively, the “Director Defendants”), certain current and former officers of the Company, consisting of Kimberlee Seah, Hai Tran and Patricia Bogusz (collectively the “Officer Defendants”), Kohlberg & Co., L.L.C., Kohlberg Management V, L.L.C., Kohlberg Investors V, L.P., Kohlberg Partners V, L.P., Kohlberg TE Investors V, L.P., KOCO Investors V, L.P., and Jefferies LLC. The Company is also named as a nominal defendant in the Derivative Complaint. The Derivative Complaint was filed in the Delaware Court of Chancery as Park Employees and Retirement Board Employees’ Annuity and Benefit Fund of Chicago v. Richard M. Smith, Myron Z. Holubiak, Charlotte W. Collins, Samuel P. Frieder, David R. Huber, Richard L. Robbins, Stuart A. Samuels, Gordon H. Woodward, Kimberlee C. Seah, Hai V.Tran, Patricia Bogusz, Kohlberg & Co., L.L.C., Kohlberg Management V, L.L.C., Kohlberg Investors V, L.P., Kohlberg Partners V, L.P., Kohlberg TE Investors V, L.P., KOCO Investors V, L.P., Jefferies LLC and BioScrip, Inc., C.A. No. 11000-VCG (Del. Ch. Ct., May 7, 2015). The Derivative Complaint alleges generally that certain defendants breached their fiduciary duties with respect to the Company’s public disclosures, oversight of Company operations, secondary stock offerings and stock sales. The Derivative Complaint also contends that certain defendants aided and abetted those alleged breaches. The damages sought are not quantified but include, among other things, claims for money damages, restitution, disgorgement, equitable relief, reasonable attorneys’ fees, costs and expenses, and interest. The Derivative Complaint incorporates the same factual allegations from In re BioScrip, Inc., Securities Litigation (described below). On June 16, 2015, all defendants moved to dismiss the case. Briefing for the motion to dismiss was completed on November 30, 2015, and the court heard oral argument on the motion to dismiss on January 12, 2016. During the hearing, the court requested additional briefing, which was completed on February 12, 2016. On May 31, 2016, the court determined that the Derivative Plaintiff’s claims could not proceed as pled but granted the Derivative Plaintiff thirty days in which to make a motion to amend the Derivative Complaint. The court reserved decision on the motion to dismiss and on June 29, 2016, the Derivative Plaintiff filed a motion for leave to file an amended complaint. On October 10, 2016, all defendants moved to dismiss the amended complaint and the Court heard oral argument on January 19, 2017. On April 18, 2017, the Court granted the defendants’ motion to dismiss. Plaintiffs filed a notice of appeal on May 12, 2017. The Company, Director Defendants and the Officer Defendants deny any allegations of wrongdoing in this lawsuit. The Company and those persons believe all of the claims in this lawsuit are without merit and intend to vigorously defend against these claims. However, there is no assurance that the defense will be successful or that insurance will be available or adequate to fund any settlement, judgment or litigation costs associated with this action. Certain of the defendants have sought indemnification from the Company pursuant to certain indemnification agreements, for which there may be no insurance coverage. Additional similar lawsuits may be filed. The Company is unable to predict the outcome or reasonably estimate a range of possible loss at this time. While no assurance can be given as to the ultimate outcome of this matter, the Company believes that the final resolution of this action is not likely to have a material adverse effect on results of operations, financial position, liquidity or capital resources. Government Regulation Various federal and state laws and regulations affecting the healthcare industry do or may impact the Company’s current and planned operations, including, without limitation, federal and state laws prohibiting kickbacks in government health programs, federal and state antitrust and drug distribution laws, and a wide variety of consumer protection, insurance and other state laws and regulations. While management believes the Company is in substantial compliance with all existing laws and regulations material to the operation of its business, such laws and regulations are often uncertain in their application to our business practices as they evolve and are subject to rapid change. As controversies continue to arise in the healthcare industry, federal and state regulation and enforcement priorities in this area can be expected to increase, the impact of which cannot be predicted. From time to time, the Company responds to investigatory subpoenas and requests for information from governmental agencies and private parties. The Company cannot predict with certainty what the outcome of any of the foregoing might be. While the Company believes it is in substantial compliance with all laws, rules and regulations that affects its business and operations, there can be no assurance that the Company will not be subject to scrutiny or challenge under one or more existing laws or that any such challenge would not be successful. Any such challenge, whether or not successful, could have a material effect upon the Company’s Consolidated Financial Statements. A violation of the Federal anti-kickback statute, for example, may result in substantial criminal penalties, as well as suspension or exclusion from the Medicare and Medicaid programs. Moreover, the costs and expenses associated with defending these actions, even where successful, can be significant. Further, there can be no assurance the Company will be able to obtain or maintain any of the regulatory approvals that may be required to operate its business, and the failure to do so could have a material effect on the Company’s Consolidated Financial Statements.

CONCENTRATION OF RISK	6 Months Ended
CONCENTRATION OF RISK	Jun. 30, 2017
Risks and Uncertainties [Abstract]
Concentration of Risk	CONCENTRATION OF RISK Customer and Credit Concentration Risk The Company provides trade credit to its customers in the normal course of business. One commercial payor, United Healthcare, accounted for approximately 21.9% and 24.4% of revenue during the three months ended June 30, 2017 and 2016, respectively, and approximately 22.4% and 25.2% of revenue during the six months ended June 30, 2017 and 2016, respectively. This contract, exclusive of certain provisions, will terminate effective September 30, 2017. In addition, Medicare accounted for approximately 7.1% and 8.3% of revenue during the three months ended June 30, 2017 and 2016, respectively, and 7.0% and 7.8% of revenue during the six months ended June 30, 2017 and 2016. Therapy Revenue Concentration Risk The Company sells products related to the Immune Globulin therapy, which represented 21.1% and 17.2% of revenue for the three months ended June 30, 2017 and 2016, respectively, and 21.6% and 17.2% of revenue for the six months ended June 30, 2017 and 2016.

INCOME TAXES

6 Months Ended

Jun. 30, 2017

Income Tax Disclosure [Abstract]

Income Taxes

INCOME TAXES

The Company’s federal and state income tax provision from continuing operations for the three months and six months ended June 30, 2017 and 2016 is summarized in the following table (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Current
Federal	$	—	$	—	$	—	$	—
State	190		25		226		25
Total current	190		25		226		25
Deferred
Federal	437		108		932		125
State	91		16		179		22
Total deferred	528		124		1,111		147
Total income tax expense	$	718	$	149	$	1,337	$	172

The income tax expense recognized for the three months and six months ended June 30, 2017 is a result of an increase in the deferred tax liability.

The Company’s reconciliation of the statutory rate from continuing operations to the effective income tax rate for the three months and six months ended June 30, 2017 and 2016 is summarized as follows (in thousands):



	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Tax benefit at statutory rate	$	(9,790	)	$	(2,844	)	$	(16,236	)	$	(6,271	)
State tax expense, net of federal taxes	190			3			226			3
Valuation allowance changes affecting income tax provision	10,266			1,926			17,242			5,314
Non-deductible transaction costs and other	52			1,064			105			1,126
Income tax expense	$	718		$	149		$	1,337		$	172

At June 30, 2017, the Company had Federal net operating loss (“NOL”) carry forwards of approximately $373.8 million, of which $14.3 million is subject to an annual limitation, which will begin expiring in 2026 and later. The Company has post-apportioned state NOL carry forwards of approximately $414.4 million, the majority of which will begin expiring in 2017 and later.

STOCK-BASED COMPENSATION	6 Months Ended
STOCK-BASED COMPENSATION	Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	STOCK-BASED COMPENSATION BioScrip Equity Incentive Plans Under the Company’s Amended and Restated 2008 Equity Incentive Plan (the “2008 Plan”), the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights (“SARs”), restricted stock grants, restricted stock units, performance shares and performance units to key employees and directors. While SARs are authorized under the 2008 Plan, they may also be issued outside of the plan. The 2008 Plan is administered by the Company’s Management Development and Compensation Committee (the “Compensation Committee”), a standing committee of the Board of Directors. On November 30, 2016, at a special meeting, the stockholders approved (i) an amendment to the Company’s Second Amended and Restated Certificate of Incorporation to increase the number of shares of Common Stock that the Company is authorized to issue from 125 million shares to 250 million shares (the “Charter Amendment”); (ii) an amendment to the 2008 Plan to (a) increase the number of shares of Common Stock in the aggregate that may be subject to awards by 5,250,000 shares, from 9,355,000 to 14,605,000 shares and (b) increase the annual grant caps under the Company’s 2008 Plan from 500,000 Options, 500,000 Stock Appreciation Rights and 350,000 Stock Grants and Restricted Stock Units that are intended to comply with the requirements of Section 162(m) of the Code to a cap of no more than a total of 3,000,000 Options, Stock Appreciation Rights, Stock Grants and Restricted Stock Units that are intended to comply with the requirements of Section 162(m) of the Code combined; and (iii) if necessary, an adjournment of the Stockholders’ Meeting if there were insufficient votes in favor of the Charter Amendment. As of June 30, 2017, 4,360,887 shares remain available for grant under the 2008 Plan. Stock Options The Company recognized compensation expense related to stock options of $0.3 million and $0.7 million during the three months ended June 30, 2017 and 2016, respectively, and $0.6 million and $1.7 million during the six months ended June 30, 2017 and 2016, respectively. Restricted Stock The Company recognized $0.1 million and a nominal amount of compensation expense related to restricted stock awards during the three months ended June 30, 2017 and 2016, respectively, and $0.3 million and a nominal amount of compensation expense during the six months ended June 30, 2017 and 2016, respectively. Stock Appreciation Rights and Market Based Cash Awards The Company recognized nominal amounts of compensation expense related to stock appreciation rights awards during the three months ended June 30, 2017 and 2016, and nominal and $0.1 million of compensation expense during the six months ended June 30, 2017 and 2016, respectively. The Company recognized nominal compensation expense and $0.2 million compensation benefit related to market based cash awards during the three months ended June 30, 2017 and 2016, respectively, and nominal and $0.1 million compensation expense during six months ended June 30, 2017 and 2016, respectively. Employee Stock Purchase Plan On May 7, 2013, the Company’s stockholders approved the BioScrip, Inc. Employee Stock Purchase Plan (the “ESPP”). The ESPP is administered by the Compensation Committee. The ESPP provides all eligible employees, as defined under the ESPP, the opportunity to purchase up to a maximum number of shares of Common Stock of the Company as determined by the Compensation Committee. Participants in the ESPP may acquire the Common Stock at a cost of 85% of the lower of the fair market value on the first or last day of the quarterly offering period. The Company filed a Registration Statement on Form S-8 to register 750,000 shares of Common Stock, par value $0.0001 per share, for issuance under the ESPP. As of June 30, 2017, 136,713 shares remained available for grant under the ESPP. Since inception, the ESPP’s third-party service provider has purchased 613,287 shares on the open market and delivered these shares to the Company’s employees pursuant to the ESPP. During the three months ended June 30, 2017 and 2016, and the six months ended June 30, 2017 and 2016, the Company incurred less than $0.1 million of expense related to the ESPP.

BASIS OF PRESENTATION (Policies)	6 Months Ended
BASIS OF PRESENTATION (Policies)	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	These Unaudited Consolidated Financial Statements should be read in conjunction with the Audited Consolidated Financial Statements, including the notes thereto, and other information included in the Annual Report on Form 10-K of BioScrip, Inc. and its wholly-owned subsidiaries (the “Company”) for the year ended December 31, 2016 (the “Annual Report”) filed with the U.S. Securities and Exchange Commission (“SEC”). These Unaudited Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, and the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The information furnished in these Unaudited Consolidated Financial Statements reflects all adjustments, including normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. Operating results for the three months and six months ended June 30, 2017 require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes and are not necessarily indicative of the results that may be expected for the full year ending December 31, 2017.
Consolidation	The Unaudited Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Business Combinations	Business Combinations Business combinations are accounted for using the acquisition method as of the acquisition date, the date on which control is transferred to the Company. Goodwill is measured at the acquisition date as the fair value of the consideration transferred, plus the fair value of the identifiable assets acquired and liabilities assumed. Transaction costs are expensed as incurred. Contingent consideration payable is measured at fair value at the acquisition date. Contingent consideration classified as equity is not re-measured and settlement is accounted for within equity.
Cash and Cash Equivalents and Restricted Cash	Cash and Cash Equivalents and Restricted Cash Highly liquid investments with a maturity of three months or less when purchased are classified as cash equivalents. Restricted cash consists of cash balances held by financial institutions as collateral for letters of credit. These balances are reclassified to cash and cash equivalents when the underlying obligation is satisfied, or in accordance with the governing agreement. Restricted cash balances expected to become unrestricted during the next twelve months are recorded as current assets.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-11—Earnings Per Share (Topic 260), Distinguishing Liabilities From Equity (Topic 480), and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 eliminates the requirement that a down round feature precludes equity classification when assessing whether an instrument is indexed to an entity’s own stock. A freestanding equity-linked financial instrument no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. The effective date for ASU 2017-11 is for annual or any interim periods beginning after December 15, 2018. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. In May 2017, the FASB issued ASU 2017-09—Compensation–Stock Compensation (Topic 718): Scope of Modification Accounting. ASU 2017-09 modifies when a change to the terms or conditions of a share-based payment award must be accounted for as a modification. The new guidance requires modification accounting if the fair value, vesting condition or the classification of the award is not the same immediately before and after a change to the terms and conditions of the award. The effective date for ASU 2017-09 is for annual or any interim periods beginning after December 15, 2017. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. In January 2017, the FASB issued ASU 2017-04—Intangibles–Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. ASU 2017-04 modifies the accounting for goodwill impairment. The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The effective date for ASU 2017-04 is for annual or any interim periods beginning after December 15, 2019. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. In November 2016, the FASB issued ASU 2016-18—Statement of Cash Flows (Topic 230): Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The effective date for ASU 2016-18 is for annual or any interim periods beginning after December 15, 2017. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. In August 2016, the FASB issued ASU 2016-15—Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 provides guidance for eight specific cash flow issues with respect to how cash receipts and cash payments are classified in the statements of cash flows, with the objective of reducing diversity in practice. The effective date for ASU 2016-15 is for annual periods beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s consolidated financial statements. In February 2016, the FASB issued ASU 2016-02—Leases (Topic 842), requiring lessees to recognize a right-of-use asset and a lease liability on the balance sheet for all leases with the exception of short-term leases. For lessees, leases will continue to be classified as either operating or finance leases in the income statement. The effective date of the new standard for public companies is for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition and requires application of the new guidance at the beginning of the earliest comparative period presented. The Company is evaluating the effect that the updated standard will have on its consolidated financial statements. In May 2014, the FASB issued ASU 2014-09—Revenue from Contracts with Customers (Topic 606). The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The FASB delayed the effective date to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. In addition, in March and April 2016, the FASB issued new guidance intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. Both amendments permit the use of either a retrospective or cumulative effect transition method and are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early application permitted. The Company has not elected early adoption and will apply the modified retrospective approach upon adoption. The Company continues to evaluate the impact of the adoption of the new revenue standard on its consolidated financial statements.

BASIS OF PRESENTATION (Tables)

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Accounts Receivable Aging



	June 30, 2017							December 31, 2016
	0 - 180 days		Over 180 days		Total			0 - 180 days		Over 180 days		Total
Government	$	18,714	$	7,512	$	26,226		$	19,891	$	8,278	$	28,169
Commercial	84,190		23,589		107,779			97,744		19,848		117,592
Patient	5,195		9,540		14,735			3,955		6,825		10,780
Gross accounts receivable	$	108,099	$	40,641	148,740			$	121,590	$	34,951	156,541
Allowance for doubtful accounts					(45,651		)					(44,730		)
Net accounts receivable					$	103,089						$	111,811

LOSS PER SHARE (Tables)

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Loss Per Share

The following table sets forth the computation of basic and diluted loss per common share (in thousands, except for per share amounts):



	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Numerator:
Loss from continuing operations, net of income taxes	$	(28,695	)	$	(8,309	)	$	(47,686	)	$	(18,079	)
Income (loss) from discontinued operations, net of income taxes	(503		)	75			(940		)	308
Net loss	$	(29,198	)	$	(8,234	)	$	(48,626	)	$	(17,771	)
Accrued dividends on preferred stock	(2,303		)	(2,056		)	(4,517		)	(4,054		)
Deemed dividend on preferred stock	(175		)	(173		)	(349		)	(345		)
Loss attributable to common stockholders	$	(31,676	)	$	(10,463	)	$	(53,492	)	$	(22,170	)

Denominator - Basic and Diluted:
Weighted average common shares outstanding	121,189			73,186			119,993			70,978

Loss per Common Share:
Loss from continuing operations, basic and diluted	$	(0.26	)	$	(0.14	)	$	(0.44	)	$	(0.32	)
Loss from discontinued operations, basic and diluted	—			—			(0.01		)	—
Loss per common share, basic and diluted	$	(0.26	)	$	(0.14	)	$	(0.45	)	$	(0.32	)

STOCKHOLDERS' DEFICIT (Tables)

6 Months Ended

Jun. 30, 2017

Equity [Abstract]

Carrying value and activity of Preferred Shares

The following table sets forth the activity recorded during the six months ended June 30, 2017 related to the Series C Preferred Stock (in thousands):



Series C Preferred Stock carrying value at December 31, 2016	$	69,540
Accretion of discount related to issuance costs	323
Dividends recorded through June 30, 2017¹	4,366
Series C Preferred Stock carrying value June 30, 2017	$	74,229

¹Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.

The following table sets forth the activity recorded during the six months ended June 30, 2017 related to the Series A Preferred Stock (in thousands):



Series A Preferred Stock carrying value at December 31, 2016	$	2,462
Accretion of discount related to issuance costs	26
Dividends recorded through June 30, 2017¹	151
Series A Preferred Stock carrying value June 30, 2017	$	2,639

¹Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.

ACQUISITIONS (Tables)

6 Months Ended

Jun. 30, 2017

Business Combinations [Abstract]

Schedule of Consideration Transferred in Acquisition

The following table sets forth the consideration transferred in connection with the acquisition of Home Solutions as of September 9, 2016 (in thousands):



Cash	$	67,516
Equity issued at closing	9,938
Capital lease obligation assumed	301
Fair value of contingent consideration	15,400
Total consideration	$	93,155

Schedule of Assets Acquired and Liabilities Assumed

The following table sets forth the preliminary estimate of fair value of the assets acquired and liabilities assumed upon acquisition of Home Solutions (in thousands):



Accounts receivable	$	11,956
Inventories	3,199
Prepaids and other assets	852
Total current assets	$	16,007
Property and equipment	4,651
Goodwill	57,218
Managed care contracts	24,700
Licenses	5,400
Trade name	1,800
Non-compete agreements	200
Other non-current assets	891
Total assets	$	110,867
Accounts payable	14,576
Accrued liabilities	3,136
Current liabilities	$	17,712
Total fair value of cash and contingent consideration	$	93,155

RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES, NET (Tables)

6 Months Ended

Jun. 30, 2017

Restructuring and Related Activities [Abstract]

Schedule of Restructuring, Acquisition, Integration, and Other Expenses, Net



	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Restructuring expense	$	3,648	$	1,316	$	6,854	$	3,932
Acquisition and integration expense	263		2,924		280		2,924
Change in fair value of contingent consideration	—		51		—		102
Total restructuring, acquisition, integration, and other expense, net	$	3,911	$	4,291	$	7,134	$	6,958

DEBT (Tables)

6 Months Ended

Jun. 30, 2017

Debt Disclosure [Abstract]

Summary of Long-term Debt

As of June 30, 2017 and December 31, 2016, the Company’s debt consisted of the following (in thousands):



	June 30, 2017			December 31, 2016
Senior Credit Facilities	$	—		$	265,507
First Lien Note Facility, net of unamortized discount	198,000			—
Second Lien Note Facility, net of unamortized discount	82,931			—
2021 Notes, net of unamortized discount	197,008			196,670
Capital leases	3,134			2,209
Less: Deferred financing costs	(3,668		)	(12,452		)
Total Debt	477,405			451,934
Less: Current portion	(1,731		)	(18,521		)
Long-term debt, net of current portion	$	475,674		$	433,413

Schedule of Carrying and Estimated Fair Values of Financial Instruments

The following details our financial instruments where the carrying value and the fair value differ (in thousands):



Financial Instrument	Carrying Value as of June 30, 2017		Markets for Identical Item (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
First Lien Note Facility	$	198,000	$	—	$	198,000	$	—
Second Lien Note Facility	82,931		—		82,931		—
2017 Warrants	16,908		—		16,908		—
2021 Notes	197,008		—		178,109		—
Total	$	494,847	$	—	$	475,948	$	—

INCOME TAXES (Tables)

6 Months Ended

Jun. 30, 2017

Income Tax Disclosure [Abstract]

Schedule of Federal and State Income Tax Provision (Benefit)

The Company’s federal and state income tax provision from continuing operations for the three months and six months ended June 30, 2017 and 2016 is summarized in the following table (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Current
Federal	$	—	$	—	$	—	$	—
State	190		25		226		25
Total current	190		25		226		25
Deferred
Federal	437		108		932		125
State	91		16		179		22
Total deferred	528		124		1,111		147
Total income tax expense	$	718	$	149	$	1,337	$	172

Reconciliation of the Income Tax Rate



	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
Tax benefit at statutory rate	$	(9,790	)	$	(2,844	)	$	(16,236	)	$	(6,271	)
State tax expense, net of federal taxes	190			3			226			3
Valuation allowance changes affecting income tax provision	10,266			1,926			17,242			5,314
Non-deductible transaction costs and other	52			1,064			105			1,126
Income tax expense	$	718		$	149		$	1,337		$	172

BASIS OF PRESENTATION - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Restricted cash	$ 5,055	$ 0

BASIS OF PRESENTATION - Accounts Receivable Aging (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	$ 148,740	$ 156,541
Allowance for doubtful accounts	(45,651)	(44,730)
Net accounts receivable	103,089	111,811
Government
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	26,226	28,169
Commercial
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	107,779	117,592
Patient
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	14,735	10,780
Receivables 0 to 180 Days Past Due
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	108,099	121,590
Receivables 0 to 180 Days Past Due \| Government
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	18,714	19,891
Receivables 0 to 180 Days Past Due \| Commercial
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	84,190	97,744
Receivables 0 to 180 Days Past Due \| Patient
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	5,195	3,955
Receivables Over 180 Days Past Due
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	40,641	34,951
Receivables Over 180 Days Past Due \| Government
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	7,512	8,278
Receivables Over 180 Days Past Due \| Commercial
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	23,589	19,848
Receivables Over 180 Days Past Due \| Patient
Accounts, Notes, Loans and Financing Receivable [Line Items]
Gross accounts receivable	$ 9,540	$ 6,825

LOSS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Earnings Per Share [Abstract]
Common stock, par value (in dollars per share)	$ 0.0001		$ 0.0001		$ 0.0001
Numerator:
Loss from continuing operations, net of income taxes	$ (28,695)	$ (8,309)	$ (47,686)	$ (18,079)
(Loss) income from discontinued operations, net of income taxes	(503)	75	(940)	308
Net loss	(29,198)	(8,234)	(48,626)	(17,771)
Accrued dividends on preferred stock	(2,303)	(2,056)	(4,517)	(4,054)
Deemed dividends on preferred stock	(175)	(173)	(349)	(345)
Loss attributable to common stockholders	$ (31,676)	$ (10,463)	$ (53,492)	$ (22,170)
Denominator - Basic and Diluted:
Weighted average number of common shares outstanding, basic and diluted (in shares)	121,189	73,186	119,993	70,978
Loss per Common Share:
Loss from continuing operations, basic and diluted (in dollars per share)	$ (0.26)	$ (0.14)	$ (0.44)	$ (0.32)
Loss from discontinued operations, basic and diluted (in dollars per share)	0.00	0.00	(0.01)	0.00
Loss per common share, basic and diluted (in dollars per share)	$ (0.26)	$ (0.14)	$ (0.45)	$ (0.32)
Antidilutive securities excluded from computation of earnings per share (in shares)	18,300	14,000	18,400	15,500
Series A Preferred Stock
Class of Stock [Line Items]
Convertible preferred stock series, par value (in dollars per share)	$ 0.0001		$ 0.0001		0.0001
Series C Preferred Stock
Class of Stock [Line Items]
Convertible preferred stock series, par value (in dollars per share)	$ 0.0001		$ 0.0001		$ 0.0001

STOCKHOLDERS' DEFICIT - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands					6 Months Ended
	Jun. 22, 2016	Jun. 14, 2016	Jul. 31, 2015	Mar. 09, 2015	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	May 02, 2016	Jun. 30, 2015
Class of Warrant or Right [Line Items]
Proceeds from issuance of equity and temporary equity			$ 1,100
Amount of equity able to raise								$ 200,000
Value of stock issued in secondary offering					$ 20,776	$ 83,267
Common Stock \| Secondary Offering
Class of Warrant or Right [Line Items]
Share price (in dollars per share)	$ 2.00
Stock issued (in shares)	45,200,000
Value of stock issued in secondary offering	$ 83,300
Common Stock \| Over-Allotment Option
Class of Warrant or Right [Line Items]
Stock issued (in shares)	5,200,000
PIPE Warrants
Class of Warrant or Right [Line Items]
Additional contribution by investors				$ 500
PIPE Warrants \| Common Stock
Class of Warrant or Right [Line Items]
Common stock reserved for future issuance (in shares)					3,600,000
Class A Warrants
Class of Warrant or Right [Line Items]
Warrants issued (in shares)			31,025	1,800,000
Exercise price of warrants (in dollars per share)				$ 5.17					$ 5.17
Class B Warrants
Class of Warrant or Right [Line Items]
Warrants issued (in shares)			31,025	1,800,000
Exercise price of warrants (in dollars per share)				$ 6.45					6.45
Class A Warrants Prior to Addendum
Class of Warrant or Right [Line Items]
Exercise price of warrants (in dollars per share)				5.295
Class B Warrants Prior to Addendum
Class of Warrant or Right [Line Items]
Exercise price of warrants (in dollars per share)				$ 6.595
Series A Preferred Stock
Class of Warrant or Right [Line Items]
Shares issued (in shares)			10,822	625,000	21,645		21,645
Share price (in dollars per share)			$ 100	$ 100.00
Proceeds from issuance of equity and temporary equity				$ 62,500
Redemption price (in dollars per share)				$ 5.17
Exercise price of warrants (in dollars per share)									$ 5.17
Series A convertible preferred stock, shares authorized (in shares)				825,000	825,000		825,000
Dividend accrual rate					11.50%
Convertible preferred stock series, shares outstanding (in shares)					21,645		21,645
Convertible preferred stock series, liquidation preference					$ 2,754		$ 2,603
Series A Preferred Stock \| PIPE Warrants
Class of Warrant or Right [Line Items]
Shares issued (in shares)					10,823
Series B Preferred Stock
Class of Warrant or Right [Line Items]
Shares converted (in shares)		614,177
Convertible preferred stock series, shares outstanding (in shares)					0
Series C Preferred Stock
Class of Warrant or Right [Line Items]
Shares issued (in shares)					614,177		614,177
Series A convertible preferred stock, shares authorized (in shares)					625,000		625,000
Shares issued in conversion (in shares)		614,177
Dividend rate of non-cash dividend payable					11.50%
Convertible preferred stock series, shares outstanding (in shares)					614,177		614,177
Convertible preferred stock series, liquidation preference					$ 79,858		$ 75,491

STOCKHOLDERS' DEFICIT - Activity Related to Series A and C Preferred Stock (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2017 USD ($)
Series A Preferred Stock
Increase (Decrease) in Temporary Equity [Roll Forward]
Beginning Balance	$ 2,462
Accretion of discount related to issuance costs	26
Dividends recorded	151
Ending Balance	2,639
Series C Preferred Stock
Increase (Decrease) in Temporary Equity [Roll Forward]
Beginning Balance	69,540
Accretion of discount related to issuance costs	323
Dividends recorded	4,366
Ending Balance	$ 74,229

STOCKHOLDERS' DEFICIT - Home Solutions Transaction (Details) - Home Solutions $ / shares in Units, $ in Thousands	Sep. 09, 2016 USD ($) Days $ / shares shares
Business Acquisition [Line Items]
Cash consideration paid \| $	$ 67,516
Equity issued in acquisition (in shares)	3,750,000
Restricted Stock Units (RSUs) \| Tranche A
Business Acquisition [Line Items]
Equity issued in acquisition (in shares)	3,100,000
Price of shares issued in acquisition (in dollars per share) \| $ / shares	$ 4.00
Consecutive trading days \| Days	20
Restricted Stock Units (RSUs) \| Tranche B
Business Acquisition [Line Items]
Equity issued in acquisition (in shares)	4,000,000
Price of shares issued in acquisition (in dollars per share) \| $ / shares	$ 5.00
Consecutive trading days \| Days	20

STOCKHOLDERS' DEFICIT - First Quarter 2017 Private Placement (Details) - USD ($) $ / shares in Units, $ in Thousands			6 Months Ended
	Jun. 29, 2017	Mar. 01, 2017	Jun. 30, 2017	Jun. 30, 2016
Class of Stock [Line Items]
Net proceeds from issuance of equity, net of issuance costs			$ 20,776	$ 83,267
Private Placement \| Common Stock
Class of Stock [Line Items]
Stock issued (in shares)	6,359,350	3,300,000.0
Net proceeds from issuance of equity, net of issuance costs	$ 15,900	$ 5,100
Stock offering price (in dollars per share)	$ 2.50	$ 1.5366

STOCKHOLDERS' DEFICIT - 2017 Warrants (Details) - Common Stock - 2017 Warrants - $ / shares	Jun. 29, 2017	Jun. 30, 2017
Class of Warrant or Right [Line Items]
Warrant exercise threshold	4.99%
Warrant holder outstanding common stock ownership limitation	19.99%
Exercise price of warrants (in dollars per share)		$ 2.00

STOCKHOLDERS' DEFICIT - Second Quarter 2017 Private Placement (Details) - USD ($) $ / shares in Units, $ in Thousands			6 Months Ended
	Jun. 29, 2017	Mar. 01, 2017	Jun. 30, 2017	Jun. 30, 2016
Class of Stock [Line Items]
Net proceeds from issuance of equity, net of issuance costs			$ 20,776	$ 83,267
Private Placement \| Common Stock
Class of Stock [Line Items]
Stock issued (in shares)	6,359,350	3,300,000.0
Stock offering price (in dollars per share)	$ 2.50	$ 1.5366
Net proceeds from issuance of equity, net of issuance costs	$ 15,900	$ 5,100
Associated costs with private placement	$ 200

ACQUISITIONS - Additional Information (Details) - Home Solutions	Sep. 09, 2016 shares
Business Acquisition [Line Items]
Equity issued in acquisition (in shares)	3,750,000
Tranche A \| Restricted Stock Units (RSUs)
Business Acquisition [Line Items]
Equity issued in acquisition (in shares)	3,100,000
Tranche B \| Restricted Stock Units (RSUs)
Business Acquisition [Line Items]
Equity issued in acquisition (in shares)	4,000,000

ACQUISITIONS - Consideration Transferred in Acquisition (Details) - Home Solutions $ in Thousands	Sep. 09, 2016 USD ($)
Business Acquisition [Line Items]
Cash	$ 67,516
Equity issued at closing	9,938
Capital lease obligation assumed	301
Fair value of contingent consideration	15,400
Total consideration	$ 93,155

ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016	Sep. 09, 2016
Business Acquisition [Line Items]
Goodwill	$ 365,947	$ 365,947
Home Solutions
Business Acquisition [Line Items]
Accounts receivable			$ 11,956
Inventories			3,199
Prepaids and other assets			852
Total current assets			16,007
Property and equipment			4,651
Goodwill			57,218
Other non-current assets			891
Total assets			110,867
Accounts payable			14,576
Accrued liabilities			3,136
Current liabilities			17,712
Total fair value of cash and contingent consideration			93,155
Home Solutions \| Managed care contracts
Business Acquisition [Line Items]
Intangible assets			24,700
Home Solutions \| Licenses
Business Acquisition [Line Items]
Intangible assets			5,400
Home Solutions \| Trade name
Business Acquisition [Line Items]
Intangible assets			1,800
Home Solutions \| Non-compete agreements
Business Acquisition [Line Items]
Intangible assets			$ 200

RESTRUCTURING, ACQUISITION, INTERGRATION, AND OTHER EXPENSES, NET (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Restructuring and Related Activities [Abstract]
Restructuring expense	$ 3,648	$ 1,316	$ 6,854	$ 3,932
Acquisition and integration expense	263	2,924	280	2,924
Change in fair value of contingent consideration	0	51	0	102
Total restructuring, acquisition, integration, and other expense, net	$ 3,911	$ 4,291	$ 7,134	$ 6,958

DEBT - Summary of Long-term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Less: Deferred financing costs	$ (3,668)	$ (12,452)
Total Debt	477,405	451,934
Less: Current portion	(1,731)	(18,521)
Long-term debt, net of current portion	475,674	433,413
Senior Credit Facilities
Debt Instrument [Line Items]
Long-term debt	0	265,507
First Lien Note Facility, net of unamortized discount
Debt Instrument [Line Items]
Long-term debt	198,000	0
Second Lien Note Facility, net of unamortized discount
Debt Instrument [Line Items]
Long-term debt	82,931	0
2021 Notes
Debt Instrument [Line Items]
Long-term debt	197,008	196,670
Capital leases
Debt Instrument [Line Items]
Capital leases	$ 3,134	$ 2,209

DEBT - Additional Information (Details) - USD ($)			6 Months Ended
DEBT - Additional Information (Details) - USD ($)	Jun. 29, 2017	Mar. 01, 2017	Jun. 30, 2017	Jun. 30, 2016	Jan. 06, 2017	Feb. 11, 2014	Jul. 31, 2013
Debt Instrument [Line Items]
Net proceeds from issuance of equity, net of issuance costs			$ 20,776,000	$ 83,267,000
Common Stock \| 2017 Warrants
Debt Instrument [Line Items]
Warrant exercise threshold	4.99%
Warrants classified within equity at fair value			$ 16,900,000
Private Placement \| Common Stock
Debt Instrument [Line Items]
Net proceeds from issuance of equity, net of issuance costs	$ 15,900,000	$ 5,100,000
Associated costs with private placement	200,000
Term Loan B Facility \| Senior Secured Debt
Debt Instrument [Line Items]
Face amount of debt instruments							$ 250,000,000.0
Delayed Draw Term Loan Facility \| Senior Secured Debt
Debt Instrument [Line Items]
Face amount of debt instruments							150,000,000.0
Priming Credit Agreement \| Line of Credit
Debt Instrument [Line Items]
Face amount of debt instruments					$ 25,000,000
First Lien Notes \| Senior Secured Debt
Debt Instrument [Line Items]
Face amount of debt instruments	200,000,000
Amortization installment percentage of principal			0.625%
Early repayment premium base rate			5.00%
Principal prepayment limit			$ 50,000,000
Default penalty interest rate increase			2.00%
First Lien Notes \| Senior Secured Debt \| Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate			6.00%
First Lien Notes \| Senior Secured Debt \| LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate			7.00%
First Lien Notes \| Senior Secured Debt \| Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate			1.00%
First Lien Notes \| Senior Secured Debt \| Redemption Period One
Debt Instrument [Line Items]
Early repayment premium rate			4.00%
First Lien Notes \| Senior Secured Debt \| Redemption Period Two
Debt Instrument [Line Items]
Early repayment premium rate			2.00%
First Lien Notes \| Senior Secured Debt \| Redemption Period Three
Debt Instrument [Line Items]
Early repayment premium rate			0.00%
Second Lien Notes \| Senior Secured Debt
Debt Instrument [Line Items]
Face amount of debt instruments	100,000,000
Early repayment premium base rate			5.00%
Default penalty interest rate increase			2.00%
Second Lien Notes \| Senior Secured Debt \| Option One
Debt Instrument [Line Items]
Basis spread on variable rate			9.25%
Second Lien Notes \| Senior Secured Debt \| Option Two
Debt Instrument [Line Items]
Basis spread on variable rate			11.25%
Second Lien Notes \| Senior Secured Debt \| Option Three
Debt Instrument [Line Items]
Basis spread on variable rate			10.25%
Second Lien Notes \| Senior Secured Debt \| Option Three, Half Cash
Debt Instrument [Line Items]
Basis spread on variable rate			4.625%
Second Lien Notes \| Senior Secured Debt \| Option Three, Half Capitalized Interest
Debt Instrument [Line Items]
Basis spread on variable rate			5.625%
Second Lien Notes \| Senior Secured Debt \| Redemption Period One
Debt Instrument [Line Items]
Early repayment premium rate			4.00%
Second Lien Notes \| Senior Secured Debt \| Redemption Period Two
Debt Instrument [Line Items]
Early repayment premium rate			2.00%
Second Lien Notes \| Senior Secured Debt \| Redemption Period Three
Debt Instrument [Line Items]
Early repayment premium rate			0.00%
Second Lien Delayed Draw Notes \| Senior Secured Debt
Debt Instrument [Line Items]
Additional debt allowed under debt agreements	$ 10,000,000
Period after closing of ability to issue new debt	18 months
Senior Unsecured 8.875% Notes
Debt Instrument [Line Items]
Face amount of debt instruments						$ 200,000,000.0
Stated rate on debt			8.875%			8.875%
Debt discount						$ 5,000,000
Revolving Credit Facility \| Revolving Credit Facility \| Senior Secured Debt
Debt Instrument [Line Items]
Face amount of debt instruments							$ 75,000,000.0
Minimum \| First Lien Notes \| Senior Secured Debt \| Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate			0.50%
Minimum \| First Lien Notes \| Senior Secured Debt \| LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate			1.00%
Minimum \| Second Lien Notes \| Senior Secured Debt \| Option One \| LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate			1.25%

DEBT - Carrying and Estimated Fair Values of Financial Instruments (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total, carrying value	$ 494,847
First Lien Note Facility, net of unamortized discount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, carrying value	198,000	$ 0
Second Lien Note Facility, net of unamortized discount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, carrying value	82,931	0
2021 Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, carrying value	197,008	$ 196,670
Markets for Identical Item (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants, fair value	0
Total, fair value	0
Markets for Identical Item (Level 1) \| First Lien Note Facility, net of unamortized discount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value	0
Markets for Identical Item (Level 1) \| Second Lien Note Facility, net of unamortized discount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value	0
Markets for Identical Item (Level 1) \| 2021 Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants, fair value	16,908
Total, fair value	475,948
Significant Other Observable Inputs (Level 2) \| First Lien Note Facility, net of unamortized discount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value	198,000
Significant Other Observable Inputs (Level 2) \| Second Lien Note Facility, net of unamortized discount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value	82,931
Significant Other Observable Inputs (Level 2) \| 2021 Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value	178,109
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants, fair value	0
Total, fair value	0
Significant Unobservable Inputs (Level 3) \| First Lien Note Facility, net of unamortized discount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value	0
Significant Unobservable Inputs (Level 3) \| Second Lien Note Facility, net of unamortized discount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value	0
Significant Unobservable Inputs (Level 3) \| 2021 Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, fair value	0
2017 Warrants \| Common Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants, carrying value	16,908
Warrants, fair value	$ 16,900

COMMITMENTS AND CONTINGENCIES (Details) - Settled Litigation - Pharmacy Services Assets Sale - Walgreens $ in Millions	Dec. 28, 2016 USD ($)
Loss Contingencies
Percent of total sales claimed in violation of agreement	3.00%
Damages awarded	$ 5.8
Percent awarded of total sought	20.00%

CONCENTRATION OF RISK (Details)	3 Months Ended		6 Months Ended
CONCENTRATION OF RISK (Details)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Customer Concentration Risk \| United Healthcare
Concentration Risk [Line Items]
Percentage of concentration risk	21.90%	24.40%	22.40%	25.20%
Customer Concentration Risk \| Medicare
Concentration Risk [Line Items]
Percentage of concentration risk	7.10%	8.30%	7.00%	7.80%
Product Concentration Risk \| Immune Globulin
Concentration Risk [Line Items]
Percentage of concentration risk	21.10%	17.20%	21.60%	17.20%

INCOME TAXES - Schedule of Federal and State Income Tax Provision (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Federal	$ 0	$ 0	$ 0	$ 0
State	190	25	226	25
Total current	190	25	226	25
Federal	437	108	932	125
State	91	16	179	22
Total deferred	528	124	1,111	147
Total income tax expense	$ 718	$ 149	$ 1,337	$ 172

INCOME TAXES - Reconciliation of the Income Tax Rate (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Tax benefit at statutory rate	$ (9,790)	$ (2,844)	$ (16,236)	$ (6,271)
State tax expense, net of federal taxes	190	3	226	3
Valuation allowance changes affecting income tax provision	10,266	1,926	17,242	5,314
Non-deductible transaction costs and other	52	1,064	105	1,126
Total income tax expense	$ 718	$ 149	$ 1,337	$ 172

INCOME TAXES - Additional Information (Details) $ in Millions	Jun. 30, 2017 USD ($)
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 373.8
Net operating loss carryforwards subject to annual limitation	14.3
State
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 414.4

STOCK-BASED COMPENSATION (Details) - USD ($) $ / shares in Units, $ in Millions			3 Months Ended		6 Months Ended
	Nov. 30, 2016	May 07, 2013	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Nov. 29, 2016
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Par value of common stock (in dollars per share)			$ 0.0001		$ 0.0001		$ 0.0001
Equity Option
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation expense			$ 0.3	$ 0.7	$ 0.6	$ 1.7
Stock Appreciation Rights (SARs)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation expense					0.1
Restricted Stock
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation expense			$ 0.1		$ 0.3
Market Based Cash Awards
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based compensation expense				(0.2)		0.1
Employee Stock
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of shares authorized (in shares)		750,000
Number of shares available for grant (in shares)			136,713		136,713
Share-based compensation expense			$ 0.1	$ 0.1	$ 0.3	$ 0.3
Purchase price of common stock, percent		85.00%
Par value of common stock (in dollars per share)		$ 0.0001
Shares purchased on the open market for award (in shares)					613,287
Charter Amendment
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of shares authorized (in shares)	250,000,000							125,000,000
2008 Plan
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of shares authorized (in shares)	3,000,000
Number of shares available for grant (in shares)			4,360,887		4,360,887
2008 Plan \| Equity Option
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of shares authorized (in shares)								500,000
2008 Plan \| Stock Appreciation Rights (SARs)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of shares authorized (in shares)								500,000
2008 Plan \| Restricted Stock
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of shares authorized (in shares)								350,000
2008 Plan \| Common Stock
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of shares authorized (in shares)	14,605,000							9,355,000
Adjustment to number of shares authorized (in shares)	5,250,000